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Abstract
Background The laparoscopic approach is increasingly
applied in colorectal surgery. Although laparoscopic sur-
gery in colon cancer has been proved to be safe and fea-
sible with equivalent long-term oncological outcome
compared to open surgery, safety and long-term oncolog-
ical outcome of laparoscopic surgery for rectal cancer
remain controversial. Laparoscopic rectal cancer surgery
might be efficacious, but indications and limitations are not
clearly defined. Therefore, the European Association for
Endoscopic Surgery (EAES) has developed this clinical
practice guideline.
Methods An international expert panel was invited to
appraise the current literature and to develop evidence-based
recommendations. The expert panel constituted for a con-
sensus development conference in May 2010. Thereafter, the
recommendations were presented at the annual congress
of the EAES in Geneva in June 2010 in a plenary session.
A second consensus process (Delphi process) of the recom-
mendations with the explanatory text was necessary due to
the changes after the consensus conference.
Results Laparoscopic surgery for extraperitoneal (mid-
and low-) rectal cancer is feasible and widely accepted.
The laparoscopic approach must offer the same quality of
surgical specimen as in open surgery. Short-term outcomes
such as bowel function, surgical-site infections, pain and
hospital stay are slightly improved with the laparoscopic
approach. Laparoscopic resection of rectal cancer is not
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inferior to the open in terms of disease-free survival,
overall survival or local recurrence. Laparoscopic pelvic
dissection may impair genitourinary and sexual function
after rectal resection, like in open surgery.
Conclusions Laparoscopic surgery for mid- and low-rectal
cancer can be recommended under optimal conditions. Still,
most level 1 evidence is for colon cancer surgery rather than
rectal cancer. Upcoming results from large randomised trials
are awaited to strengthen the evidence for improved short-
term results and equal long-term results in comparison with
the open approach.
Keywords Guidelines  Laparoscopy  Minimally
invasive surgery  Rectal cancer
The incidence of fatal cases of colorectal cancer in Europe
exceeds 200,000 per year. According to European registries,
rectal cancer has prevalence of more than 50 per 100,000
(women and men) and accounts for almost 40% of all
colorectal cancer cases [1, 2]. Despite ongoing efforts in
screening and improvements in multimodal therapy, colo-
rectal cancer is still one of the leading causes of cancer
mortality. Especially local recurrence is a major problem in
locally advanced rectal cancer. Surgery remains the main-
stay of therapy, with a standardized and quality-controlled
technique, i.e. total mesorectal excision (TME). Pioneers
have shown feasibility of laparoscopic resection of rectal
cancer, leading to a surge of this approach in recent years.
Although the laparoscopic approach in colon cancer has
been proved to be safe and feasible with equivalent long-
term oncological outcome compared to open surgery [3–5],
safety of laparoscopic surgery for rectal cancer remains
debatable. Laparoscopic resection of rectal cancer might be
efficacious, but this, as well as morbidity and oncological
outcome, need to be demonstrated. The European Associa-
tion for Endoscopic Surgery (EAES) therefore perceived the
need to hold a consensus development conference (CDC) on
laparoscopic extraperitoneal rectal cancer surgery and
thence provide clinical practice guidelines.
Methods
The EAES scientific committee commissioned the plan-
ning group in Cologne to take over the organisation of the
guideline development and to undertake a systematic lit-
erature search.
Selection of topics and experts
An international expert panel was invited to appraise
the current literature and to develop evidence-based
recommendations. An expert panel constituted for a con-
sensus development conference (CDC) in May 2010 con-
sisted of surgeons, oncologists, radiotherapist and research
scientists. Experts were selected according to their scientific
and clinical expertise as well as geographical location.
The key topics were formulated, consented and adopted
by the guideline development group. For every key topic a
coordinator was nominated, being responsible for literature
appraisal and evidence synthesis for the assigned topic.
Three or four selected subgroup members supported the
coordinator.
Literature searches and appraisal
A systematic literature search was conducted in the elec-
tronic databases MEDLINE (Pubmed) and Cochrane
Library for the years 2000–2010 (for some research ques-
tions also from 1990 to 2010) to identify clinical studies on
endoscopic rectal cancer surgery with focus on randomised
controlled trials and systematic reviews. Searches were
carried out using medical subject headings (MeSH) and
free-text words. The search was limited to studies pub-
lished in English or German language.
The results of the literature search were sent to the
expert panel for assessment of relevance for the clinical
practice guidelines (CPG) and critical appraisal.
According to the hierarchy of research evidence [6], we
tried to locate randomised controlled trials (RCT, level 1b)
or systematic reviews (SR, level 1a) dealing with the key
questions. When RCTs were of low quality or completely
lacking, non-randomised controlled clinical trials (CCT,
level 2) were included. Whenever evidence classified as
level 1 or level 2 was scarce, case–control studies or case
series (level 3 or level 4) were included.
Formulating recommendations and consensus process
All recommendations were graded according to the quality
and quantity of the underlying scientific evidence, the risk–
benefit balance and the values expressed by the panellists.
The grades of recommendations ranged from A (high-
quality evidence, usually from RCTs, demonstrating clear
benefits) over B (medium-quality evidence and/or disput-
able risk–benefit ratio) to C (low-quality evidence and/or
unclear risks and benefits). In case of limited or lacking
data to support a recommendation the panel decided that
the grade of recommendation (GoR) could be higher than
the evidence in usual cases would allow. Furthermore, for
some recommendations there was a need to modulate and
weigh the evidence locally according to value judgements,
priorities and local conditions [7].
Based on the identified studies the subgroups formulated
draft recommendations. The recommendations were discussed
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and consented in a consensus conference and thereafter
presented at the annual congress of the EAES in Geneva,
June 17, 2010 in a 90-min plenary session by members of the
panel. Notes were taken from the audience after a lively
discussion and considered in the further process. A second
consensus process (Delphi process) of the recommendations
with the explanatory text was necessary due to the changes
after the consensus conference. After two Delphi rounds,
consensus or strong consensus was reached for the majority
of recommendations [8].
Classification of consensus
Strength of consensus Percentage of agreement
Strong consensus [95% of participants
Consensus 75–95% of participants
Majority 50–75% of participants
No consensus \50% of participants
After final consensus of the recommendations a guide-
line draft for each topic was written by the subgroups of the
expert panel. The manuscripts were collected and com-
pleted to a full guideline draft. Finally, the full guideline
was consented and adopted by the expert panel. The results
are given in the text below.
Recommendations
Tumour diagnosis and staging
Tumour biopsy with histopathological processing must be
conducted prior to start of treatment. (100% [Strong con-
sensus]; GoR A: 100% [Strong consensus])
Rectal cancer is diagnosed on the histopathological
result of tumour biopsy. In presence of high clinical sus-
picion (and previous negative biopsy results) core biopsy
under general anaesthesia is recommended. Benign
pathology may not exclude further surgery in individual
cases. Radio- and/or chemotherapy will not start without
confirmed pathology.
Preoperative (and pretherapeutic) staging for precise
localisation of the tumour must include digital examination
and rigid rectoscopy. (100% [Strong consensus]; GoR A:
100% [Strong consensus])
Digital rectal examination (DRE) will allow the
assessment of tumours within the lower third of the rectum
and should be clinically staged according to Mason [9].
DRE is important to evaluate the function of the sphincter
and the distance to the anorectal ring in order to evaluate
the possibility of doing a sphincter-preserving procedure.
Rigid rectoscopy provides a more correct determination of
tumour localisation than flexible colonoscopy [10], with an
accurate assessment of the distance between the distal edge
of the tumour and the dentate line, or alternatively the anal
verge.
Assessment of tumour infiltration and local lymph nodes
(TN-staging) must be performed prior to any treatment.
Endorectal ultrasound and high-resolution magnetic res-
onance imaging are recommended. (92.9% [Consensus];
GoR A: 92.9% [Consensus])
Depth of invasion and lymph node involvement are both
important factors for prognosis. In addition, involvement of
the mesorectal fascia and tumour invasion of the meso-
rectal vessels predicts high risk of local recurrence and
poor survival [11]. Decision on therapy, especially preop-
erative treatment, is dependent on accurate tumour staging.
Tumour T- and N-stage are reliably assessed by both
endorectal ultrasound (EUS) and high-resolution magnetic
resonance imaging (MRI). Both EUS and MRI have high
sensitivity for evaluating T-stage. EUS is superior in dis-
crimination of T1 and T2 tumours, and MRI better to
evaluate involvement of the mesorectal fascia. Sensitivity
for lymph node involvement is lower, but neither of the
modalities is significantly superior to the other [12]. A
meta-analysis comparing the accuracy of EUS, MRI and
computed tomography (CT) was published in 2004 and
included 90 studies between 1985 and 2002 [13]. The
results demonstrated that EUS and MRI had similar sen-
sitivities for muscularis propria invasion (94%), but spec-
ificity of EUS (86%) was significantly higher than that of
MR imaging (69%). Identification and accurate assessment
of lymph nodes remains a major challenge. In the meta-
analysis, sensitivity estimates for EUS, CT and MR
imaging were comparably low (EUS 67%, MRI 66% and
CT 55%); specificity values were also comparable (78%
for EUS, 76% for MRI and 74% for CT). An advantage of
MRI is the ability to delineate the tumour and its rela-
tionship to the mesorectal fascia. High-resolution MRI
predicted mesorectal fascia involvement with 92% agree-
ment [14]. According to the results of the prospective
MECURY trial, high-resolution MRI has sensitivity of
94% and specificity of 92% for predicting negative cir-
cumferential margins (CRM) after surgery [15]. MRI has
been shown to be superior compared with CT in local
staging of rectal cancer and prediction of mesorectal fascia
involvement (MFR) [16].
In conclusion, EUS is most suitable for evaluating early
rectal cancer. MRI is recommended in locally advanced
rectal tumours, especially to assess mesorectal fascia
involvement. The limitations of EUS are a high degree of
user dependence and no assessment of stenotic tumours.
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Adequate pretreatment staging must include CT of the
abdomen and chest X-ray to identify metastatic disease.
(83.3% [Consensus]; GoR A: 85.7% [Consensus])
Complete staging in patients appropriate for resection
(and neoadjuvant therapy) must include physical exami-
nation with assessment of performance status, and assess-
ment of the liver and lungs to rule out metastatic disease.
Chest X-ray (or alternatively CT scan) and CT of the liver
and abdomen (or alternatively MRI or ultrasound) should
be performed [17].
Routine use of positron emission tomography (PET) or
PET-CT is not indicated unless there is suspicion of syn-
chronous metastatic disease.
(Comment: All panel members recommend assessment
of liver and lungs to identify metastatic disease. A majority
of the panel favoured the above recommendation including
CT of the abdomen instead of ultrasound only for an
adequate staging.)
Complete colonoscopy is required to rule out synchro-
nous tumours or other pathologic conditions of colon or
rectum. (78.6% [Consensus]; GoR A: 85.7% [Consensus])
Pretreatment work-up should include complete colon-
oscopy to rule out synchronous adenomas and tumours.
Synchronous tumours are expected in up to 4% of all
patients presenting with colorectal cancer [18, 19]. Alter-
natively radiological imaging (e.g. CT colonography or
barium enema) can be applied when endoscopy is techni-
cally not feasible or tumour stenosis does not allow com-
plete colonoscopy [20, 21]. In these cases colonoscopy
should be performed 3–6 months after surgery.
Pretreatment determination of the tumour marker car-
cinoembryonic antigen (CEA) should be considered.
(92.9% [Consensus]; GoR B/C: at 50% [Majority])
According to the American Society of Clinical Oncology
(ASCO) 2006 Update of Recommendation for the Use of
Tumor Markers in Gastrointestinal Cancer as well as the
European Group on Tumour Markers, CEA testing should
be ordered preoperatively in patients with rectal cancer.
CEA should not be used as a screening test [22, 23]. In rectal
as well as in combined colon and rectal cancer population,
CEA is an independent prognostic parameter [24, 25]. CEA
determination is important as a baseline for postoperative
surveillance. Especially an elevated preoperative CEA
suggests that the marker would be useful for surveillance.
Elevated preoperative CEA will not alter initial treatment
strategy or surgical therapy of the primary tumour.
Patient selection and neoadjuvant therapy
There is no indication for preoperative treatment in Inter-
national Union against Cancer (UICC) stage I tumours.
(92.9% [Consensus]; GoR A: 92.9% [Consensus])
Outside clinical trials, preoperative treatment in UICC
stage I tumours is restricted to very selective individual
cases. Organ preservation in ultra-low tumours may be one
option.
Neoadjuvant therapy should be provided for patients
staged UICC II and III. (92.9% [Consensus]; GoR B:
85.7% [Consensus])
Preoperative (instead of postoperative) regimen should
be considered in UICC stage II and III rectal cancer. Either
combined chemoradiotherapy (CRT) or short-course
radiotherapy (scRT) can be used. The main consideration
for choosing either of these two options is dependent upon
the preoperative MRI staging. If the mesorectal fascia is
involved (MRF?), a downsizing effect is important, in
which case either CRT or scRT with delayed surgery can
be recommended. If the tumour is not at risk of being
resected with a positive resection margin, but there is an
estimated risk of developing local recurrence, again either
of the two schedules can be used [26].
After the endorsement of postoperative adjuvant CRT
by a National Cancer Institute consensus conference in
1990, several randomised studies reported lower rates of
local failure with preoperative radiotherapy than with sur-
gery alone [27–29]. In addition, a Swedish trial could
demonstrate a long-lasting benefit in overall survival
compared with surgery alone [30]. After the wide adoption
of the concept of total mesorectal excision (TME) as the
surgical standard, improvement in local control and sur-
vival has been achieved with surgery alone [31]. One of the
few studies evaluating preoperative therapy together with
documented quality-controlled TME surgery is the Dutch
Colorectal Cancer Group study. Preoperative scRT with
TME was superior to TME alone in terms of local recur-
rence, whereas overall survival was similar in the two
groups [28, 32]. A Medical Research Council (MRC) trial
including 1,350 patients demonstrated a significant reduc-
tion of local recurrence in patients receiving preoperative
scRT compared with initial surgery with selective postop-
erative radiochemotherapy (4.4% versu 10.6% after
3 years). In addition, a relative improvement in disease-
free survival has been shown, whereas overall survival did
not differ between the groups [33]. A number of random-
ised trials demonstrated the effectiveness of CRT (either
post- or preoperatively). To our knowledge, there has been
no prospective study comparing preoperative CRT with
quality-controlled TME surgery alone. Two trials have
compared preoperative treatment with postoperative one.
The Uppsala trial demonstrated superiority in reduction of
local recurrence rate with scRT versus postoperative long-
course irradiation [34]. Moreover, the German Rectal
Cancer Study demonstrated the superiority of the neoad-
juvant approach over postoperative treatment. Preoperative
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therapy was associated with a significant reduction in local
recurrence and treatment-associated toxicity [35].
Both preoperative scRT and neoadjuvant CRT provide
increased local control of rectal cancer. Still, there is much
debate in Europe about the two different approaches. The
results from the small study of the Polish Colorectal Study
Group comparing scRT and CRT showed no evidence of a
difference in the rates of sphincter-preserving surgery or
local recurrence, however this study was not statistically
powered to address local recurrence [36]. Outcome data
from an Australian trial as well as a recently closed Ger-
man trial comparing both preoperative treatment strategies
are still awaited, but preliminary data indicate similar
results to the Polish trial [37, 38].
Patients with T4-staged disease where downsizing is an
issue should be treated with preoperative combined
radiochemotherapy.
Standard preoperative CRT combines radiation with a
dose of 46–50.4 Gy with 5-fluorouracil (5-FU) chemo-
therapy given either as bolus injections with Leucovorin,
prolonged continuous infusion (likely better than bolus) or
oral capecitabine [39–41]. Combined CRT is followed by
TME surgery 6–8 weeks later.
Preoperative scRT consists of single doses of 5.0 Gy in
five fractions within 1 week up to a total dose of 25 Gy.
TME surgery should be performed within 10 days from
start of radiotherapy [42]. If this schedule is not possible to
follow, surgery should be postponed to 8 weeks later [43].
Besides oncological limitations, there are no contrain-
dications for laparoscopic surgery compared with open
surgery. Morbid obesity or cardiopulmonary impairment is
not a contraindication to laparoscopic rectal cancer sur-
gery but may require additional perioperative evaluation
and monitoring. (92.9% [Consensus]; GoR B: 92.9%
[Consensus])
The panel refers to the previous EAES clinical practice
guidelines on laparoscopic resection of colonic cancer
(2004, update 2006) and on pneumoperitoneum for lapa-
roscopic surgery (2002, update 2006) [44].
Perioperative management
Explicit data on bowel preparation before laparoscopic
TME—either in favour or against—do not exist. (100%
[Strong consensus]; GoR C: 100% [Strong consensus])
For colon cancer, there is some evidence that bowel
preparation does not reduce complications (e.g. anasto-
motic leakage, surgical-site infections etc.) In addition,
there is a trend for increased complications for patients
undergoing bowel preparation [45–47]. The largest meta-
analysis, including almost 5,000 patients, demonstrated
with a high level of evidence that all kinds of mechanical
bowel preparation should be omitted before colonic sur-
gery [46].
For rectal cancer alone, explicit data do not exist.
However, in any case after low anterior rectal resection
where a deviating stoma is performed, bowel preparation
seems to be a logical prerequisite. The necessity of a
protective stoma in patients undergoing low anterior
resection with TME is still discussed. A randomised con-
trolled trial conducted by Ulrich et al. evaluated the need
for diverting ileostomy in those patients. Even if the
number of patients included in this study was quite small,
they could demonstrate a significantly higher number of
symptomatic anastomotic leakages in the non-stoma group
compared with the stoma group [48]. The results of a larger
randomised trial by Matthiesen et al. strongly support a
diverting stoma after low anterior resection [49]. As there
are many more arguments in favour of a deviating stoma
after low rectal resection in open surgery, bowel prepara-
tion can be considered in these cases.
However, data from a subgroup analysis of a large
multicentre trial did not show an influence of bowel
preparation for cancer of the mid rectum [50]. These data
are supported by Bretagnol, even if not significant [51].
Epidural catheter can be considered for pain manage-
ment. (100% [Strong consensus]; GoR C: 100% [Strong
consensus])
For open colon surgery, there is quite some evidence in
favour of epidural analgesia, but for the laparoscopic
approach it is still discussed [52]. Use of epidural or i.v.
patient-controlled analgesia (PCA) has been extensively
investigated in open surgery, but there is a paucity of data
comparing the various analgesic regimes available in lap-
aroscopic surgery. The enhanced recovery program (ERP)
has increasingly been used for laparoscopic surgery in its
unmodified form with thoracic epidural. While some cen-
tres are using this modality, other units are using PCA, and
alternative forms of postoperative pain control are being
investigated. Results of a systematic review have high-
lighted the relative lack of evidence comparing outcomes
between differing analgesic regimes. At present, there is no
convincing evidence to suggest the superiority of either
PCA or epidural in terms of length of hospital stay for
laparoscopic colorectal surgery. In the short term, no sig-
nificant difference has been identified in terms of adverse
events, although postoperative pain appears better con-
trolled in the epidural group [53].
See also www.postoppain.org, and the PROSPECT
study group.
Opioid-like drugs should be avoided. (100% [Strong
consensus]; GoR B: 100% [Strong consensus])
While opioids still remain the mainstay for postopera-
tive analgesia worldwide, their use can be associated with
adverse effects, including ileus, which can prolong hospital
Surg Endosc (2011) 25:2423–2440 2427
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stay. A number of studies have investigated the use of non-
opioid-like analgesics and regimens. A systematic review
by McCarthy et al. determined the overall efficacy of dif-
ferent analgesic regimens on postoperative analgesia and
recovery from surgery in patients undergoing various sur-
gical procedures. Relevant data such as return of bowel
function, length of hospital stay, intraoperative anaesthetic
requirement and adverse effects were also compared.
Patients receiving non-opioid-like drugs had more rapid
return to normal bowel function and decreased length of
hospital stay. Thus, opioid-like drugs, even if highly effi-
cient in pain control, should be avoided due to their neg-
ative effect on bowel function [54, 55].
Currently, there are no evidence-based recommenda-
tions for a distinct perioperative volume management.
‘‘Fast-track’’ concepts should be considered. (100%
[Strong consensus]; GoR C: 85.7% [Consensus])
The main goal of perioperative volume management is
to keep homeostasis normal. Although the ideal volume
and content of solutions for perioperative intravenous
infusion are still unknown, there is evidence that excessive
intravenous fluid administration in the perioperative phase
has a negative impact on postoperative outcome [56–59].
According to the meta-analysis of Rahbari et al., restrictive
rather than standard fluid amount reduces morbidity after
colorectal resection [60].
Patients undergoing rectal surgery must receive anti-
biotic prophylaxis. The antibiotic must be administered
before surgery (single dose) and should cover against both
aerobic and anaerobic bacteria. (100% [Strong consen-
sus]; GoR A: 100% [Strong consensus])
Research shows that administration of prophylactic
antibiotics before colorectal surgery reduces the risk of
postoperative surgical wound infection (SWI). The best
antibiotic choice, timing of administration and route of
administration remain undetermined [61]. The Cochrane
review by Nelson et al., including 182 trials (30,880 par-
ticipants) and 50 different antibiotics, demonstrated a sta-
tistically significant difference in postoperative SWI when
prophylactic antibiotics were compared with placebo/no
treatment [relative risk (RR) 0.30, 95% confidence interval
(CI) 0.22–0.41]. No statistically significant differences
were shown when comparing short- and long-term duration
of prophylaxis (RR 1.06, 95% CI 0.89–1.27), or single-
dose versus multiple-dose antibiotics (RR 1.17, 95% CI
0.67–2.05). Additional aerobic coverage and additional
anaerobic coverage both showed statistically significant
improvements in SWI rates (RR 0.41, 95% CI 0.23–0.71
and RR 0.55, 95% CI 0.35–0.85, respectively), as did
combined oral and intravenous antibiotic prophylaxis when
compared with intravenous alone (RR 0.55, 95% CI
0.41–0.74) or oral alone (RR 0.34, 95% CI 0.13–0.87).
Established gold-standard regimens were no less effective
than any other antibiotic choice. Therefore, antibiotics
covering aerobic and anaerobic bacteria must be delivered
orally and/or intravenously prior to colorectal surgery, and
one dose is sufficient [61].
Currently, there are no evidence-based recommenda-
tions for a distinct postoperative diet. ‘‘Fast-track’’ con-
cepts should be considered. (100% [Strong consensus];
GoR C: 92.9% [Consensus])
Several randomised, controlled trials showed that early
oral/enteral feeding at will did not increase morbidity and
did reduce length of stay (LOS). Nausea and vomiting can
be more frequent but do not lead to increased morbidity as
well [62, 63].
See also the Consensus Review of Optimal Perioperative
Care in Colorectal Surgery [64].
Operative techniques
Patient must be well fixed and placed in lithotomy position
with legs in padded, adjustable stirrups. (92.9% [Consen-
sus]; GoR A: 85.7% [Consensus])
Patient should be placed in modified lithotomy position.
The legs are placed in padded, adjustable stirrups. The
thighs have to be at the level of the abdominal wall with the
knees slightly flexed. Higher elevation may cause diffi-
culties in manoeuvring instruments. The patient is posi-
tioned so that the perineum is reachable from between the
legs. This allows the surgeon free access to the anus and
rectum for intraoperative endoscopy, pelvic manipulation,
perineal resection or transanal anastomosis. These are
sound principles based on experience, although not tested
by randomised trial.
It is important to place the patient carefully on the
operating room (OR) table, fixed according to local regu-
lations and in such a way that introduction of the circular
stapler through the anus can be safely performed.
Operating table has to be capable of steep Trendelen-
burg and reverse Trendelenburg positions and right and
left rotation. (100% [Strong consensus]; GoR A: 85.7%
[Consensus])
Again there is no evidence from any randomised trial;
the recommendation is based on the experience of the
panel. The Trendelenburg position is used to keep the small
bowel out of the operating field during the procedure. Both
arms are tucked, padded and protected along the patient’s
side.
A catheter is introduced into the bladder. (85.7%
[Consensus]; GoR A: 78.6% [Consensus])
As an alternative to transurethral catherization, supra-
pubic catheterization may be used. There is no evidence
that one is better than the other [65].
Positioning of the surgeon and assistants as well as
trocar position are based on the experience and the
2428 Surg Endosc (2011) 25:2423–2440
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preference of the individual surgeon. (100% [Strong con-
sensus]; GoR C: 100% [Strong consensus])
The most commonly used OR setting is a set of two
monitors; one is placed at the level of the patient’s left
shoulder and the other at the left foot level of the patient. The
surgeon and the first assistant stand at the patient’s right
side, and the nurse is positioned between the patient’s legs.
A second assistant stands at the left side of the patient.
After insufflation, four or five ports are used: one for the
laparoscope, held by the first assistant; two for the oper-
ating surgeon, introduced in the right lower abdomen for
instruments and endo-staplers. The fourth port is intro-
duced left laterally at the level of the umbilicus, and a fifth
trocar will be introduced in the left upper abdomen to
mobilize the splenic flexure. During dissection of the rec-
tum deep in the pelvis, another trocar may be introduced
above the pubis to assist the anterior aspect of dissection.
There is no clear recommendation for a distinct device,
whether bipolar or ultrasonic. Ultrasonic and advanced
bipolar devices as well as surgical stapling devices may
reduce blood loss and shorten operating time. (100%
[Strong consensus]; GoRA: 85.7% [Consensus])
Dissection may be performed by means of electrocau-
tery, ultrasonic scalpel or bipolar electrothermal device.
Most data are derived from laparoscopic colon surgery,
where it has been shown that high-energy power sources
specifically adapted for endoscopic surgery reduce operative
time and blood loss [66–69]. These data can be transferred to
laparoscopic rectal cancer surgery. Morino et al. conducted a
prospective randomised trial in patients undergoing lapa-
roscopic colorectal surgery, comparing ultrasonic dissection
(UC) with standard electrocautery. Forty of 146 randomised
patients underwent low anterior resection. Operative time
was less with UC, but did not differ significantly between the
two groups, whereas intraoperative blood loss was signifi-
cantly less with UC [70]. Zhou et al. studied 40 patients with
rectal cancer scheduled for TME, randomly divided into
ultrasonic scalpel or monopolar electrocautery shovel (ES).
This study showed no significant difference in blood loss,
but ES may generate heavy smog. Furthermore, ES can
produce a higher surface temperature when managing
tissues [71].
In all cases of low anterior resection the splenic flexure
should be mobilized. (78.6% [Consensus]; GoR B: 71.4%
[Majority])
This is a general rule, but in selected cases, the length of
the sigmoid loop will influence the choice. A long loop
may in some cases preclude mobilization. The splenic
flexure should be mobilized when needed to ensure a ten-
sion-free anastomosis. Experience suggests that this is
better done at the beginning of the operation; before dis-
section of the rectum, the left mesocolon and the sigmoid
mesocolon are dissected from medial to lateral, starting
behind the inferior mesenteric vein. The underlying retro-
peritoneal structures, including gonadal vessels, left ureter
and Gerota’s fascia, are left in place. Dissection is con-
tinued orally up to the pancreas into the lesser sac and
laterally along the fascia of Toldt on to the peritoneal
attachments of the left colon. After dividing the inferior
mesenteric vein under the pancreas and the inferior mes-
enteric artery (IMA), complete mobilization is achieved by
lateral dissection and mobilization of the splenic flexure
and the descending colon and freeing the greater omentum
from the transverse colon. Dissection will proceed with
medial dissection of distal sigmoid and rectum [2–15].
Unexpected locally advanced tumour (T4) should lead
to conversion. (100% [Strong consensus]; GoRB: 85.7%
[Consensus])
As in open surgery, oncological principles (resection
margins, high vessels ligation, lymphadenectomy etc.)
should be respected by the laparoscopic approach. (92.9%
[Consensus]; GoRB: 92.9% [Consensus])
The main goal is a tumour-free margin. Whenever
possible a free margin should be obtained. (92.9% [Con-
sensus]; GoRB: 85.7% [Consensus])
Pelvic dissection and rectal mobilization must be per-
formed according to TME principles. (100% [Strong con-
sensus]; GoRA: 92.1% [Consensus])
These are universally accepted oncological statements
and are common sense for both open and laparoscopic
surgery [72–74]. T4 tumours have been excluded from all
randomised studies in laparoscopic colon and rectal cancer
surgery. In individual cases it may be possible to proceed
with the laparoscopic approach, e.g. in limited T4 situation
where en bloc resection with small bowel or tangential/
partial resection of the bladder will allow safe resection
with free margins.
From medial to lateral, the rectum is dissected free on its
right side and posteriorly as far as possible. The pelvic
autonomic nerve plexus, the superior hypogastric sympa-
thetic nerves are carefully dissected from the mesorectum
and preserved. Anteriorly, dissection will start at the level
of the seminal vesicles in the male patient or recto-vaginal
septum in the female patient, usually after traction of the
uterus by a percutanously introduced needle.
Pelvic dissection proceeds, according to TME princi-
ples, alternating posterior, lateral left and right and anterior
dissection, along the seminal vesicles, Denonvillier fascia
and the prostate in the male or along the recto-vaginal
septum in the female patient. It is important is to preserve
the parasympathetic sacral nerve roots from S2 to S4.
Dissection proceeds down to the pelvic floor [75–88].
If the tumour is located in the midrectum, the rectum
should be transected at the level of the pelvic floor followed
by a double-stapling anastomosis. (100% [Strong consen-
sus]; GoRB: 100% [Strong consensus])
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The rectum is transected at the level of the pelvic floor
by means of a roticulating endostapler device [75–88],
using as few cartridges as possible. Use of more than two
cartridges has been reported to result in a higher anasto-
motic leakage rate [89, 90]. After rectal division, usually a
port site in the right lower abdomen is extended to 5–7 cm,
and adequately protected to deliver the specimen. Alter-
natively, a small Pfannenstiel incision is used. Once the
specimen is exteriorised, division of the remaining mes-
entery and the marginal artery are completed and the anvil
inserted. After closure of the wound or temporary closure
of the protection device, pneumoperitoneum is re-estab-
lished and a double-stapling anastomosis accomplished
(after introduction of the stapler device transanally). Con-
trol of the anastomosis should always be performed by
either endoscopy, methylene blue or instillation of air
under saline solution. The presacral space should be
drained [91] and a protective stoma created [92].
The difficulty of performing the transection is still a
point of concern. Some authors argue that it is always
possible to transect the rectum at this level, independently
of the angle of the rectum and the abdominal wall. Even-
tually introduction of the endostapler through a suprapubic
trocar may help to do this adequately at this level [79]. In a
narrow male pelvis with a reasonably big tumour located in
the mid or proximal low rectum, this action may be diffi-
cult to accomplish. Difficulties in achieving this are vari-
able, being related to high body mass index (BMI), tumour
size, distance from the anal verge and characteristics of the
pelvic outlet. These factors may be considered to be related
to anastomotic leakage and morbidity [93, 94]. Moreover,
some authors argue that an optimal perpendicular transec-
tion of the rectum during laparoscopic TME is impossible
or very demanding to achieve with the available 45
angulation roticulating stapling devices and that the opti-
mal angulation for this ideal transverse transection will
vary between 62 and 68 [95]. Some surgeons will, to
achieve this at the proper place, prefer to palpate the
tumour before transection. They will prefer at this stage to
make a Pfannenstiel incision and to apply manually the
conventional roticulator-contour device properly below the
tumour [26]. Double-stapling anastomosis will be done as
mentioned above. Use of a small Pfannenstiel incision to
perform the anastomosis at this stage should not be con-
sidered as conversion [96, 97].
Laparoscopic intracorporeal dissection means that the
dissection, the division of the vessels, the transection of the
rectum and the anastomosis must be performed laparoscop-
ically. (85.7% [Consensus]; GoR A: 85.7% [Consensus])
Intracorporeal dissection means that the dissection, the
division of the vessels, the transection of the rectum and
the anastomosis are all performed laparoscopically. If
dissection of the rectum has to be completed through a
wide Pfannenstiel incision, this is considered conversion to
laparotomy. Once dissection is completed laparoscopically,
use of a small Pfannenstiel incision for performing the
anastomosis is not considered as conversion.
Dissection is mostly performed medial to lateral. Dis-
section may be performed by means of electrocautery,
ultrasonic scalpel or bipolar electrothermal device. After
visualization of the left ureter, the IMA is dissected free
and is divided between clips, endostapler or sealing device
at high or low tie level. Low tie level will permit preser-
vation of the left colonic artery and better protection of the
hypogastric plexus on the aorta [71, 75–88].
For this laparoscopic procedure, there are alternatives
such as hand-assisted ultra-low resection [98] one hand-
size incision surgery [99] and robot-assisted rectum lapa-
roscopic resection [100–102].
Some authors have used intraoperative radiotherapy
during the laparoscopic TME in order to reduce the local
recurrence rate in locally advanced rectal cancer [103].
Furthermore in cases of difficult dissection in which con-
version is considered necessary, laparoscopic mobilization
of the splenic flexure followed by rectal dissection through
a Pfannenstiel incision will reduce operative trauma and
decrease morbidity [104].
All these variations must be regarded as experimental
and cannot be recommended until further evidence.
A continent patient with low rectal cancer, 3–4 cm from
anal verge, with no infiltration into the pelvic floor and
external sphincter can be approached by transanal inter-
sphincteric dissection and coloanal anastomosis. (100%
[Strong consensus]; GoR C: 100% [Strong consensus])
In a patient with incontinence a low Hartmann proce-
dure should be considered. (100% [Strong consensus];
GoR C: 92.9% [Consensus])
In very distal rectal cancer, e.g. 3–4 cm from anal verge,
with no in-growth of tumour in the pelvic floor or external
sphincter and with good continence grade, a coloanal
anastomosis should be considered. In this case, dissection
of the rectum will be continued through the pelvic floor to
reach the level of the sphincters [78, 84, 85].
Considering a low Hartman procedure in patients pre-
operatively not continent for stool is a sound concept,
although no studies investigating this subject exist [105].
Transanal intersphincteric dissection should be per-
formed proximal from the dentate line and below the
tumour. (92.9% [Consensus]; GoR B: 85.7% [Consensus])
Dissection should be performed proximal from the
dentate line and below the tumour. Using the anal Scott
spreading device (lone star) the anus and distal rectum are
exposed, and the rectum transected proximal to the dentate
line after intersphincteric dissection. The specimen can be
retrieved through a small Pfannenstiel incision or through
the anus, and an end-to-side or J pouch anastomosis is
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performed [74, 85, 106, 107]. The presacral space should
be drained and a defunctioning loop ileostomy created to
protect the anastomosis [91, 92].
No recommendation concerning the construction of a
colonic pouch can be made. There are no specific data for
laparoscopic surgery. In open surgery the use of a colonic
pouch guarantees better function in the first 12–18 months
and in the long term. (92.9% [Consensus]; GoR C: 92.9%
[Consensus])
Controversy exists about the type of anastomosis to use
in low anterior resection and coloanal anastomosis: straight
anastomosis, J pouch anastomosis, transverse coloplasty or
end-to-side anastomosis [106–111]. One review concludes
that probably end-to-side anastomosis will result in the
same functional quality of life as pouch anastomosis [109].
The advantages of the construction of a colonic pouch
after rectal resection in the laparoscopic setting should be
the same as in open surgery. Construction of a pouch in the
laparoscopic setting seems not to be more difficult than in
open surgery [108].
Concerning a deviating stoma there are no specific data
for laparoscopic surgery. In open surgery a deviating
stoma reduces the rate of symptomatic leakage/fistula.
(78.6% [Consensus]; GoR B: 85.7% [Consensus])
Data from open rectal cancer surgery demonstrate that a
deviating stoma reduces the rate of symptomatic leackage/
fistula. Metanalysis and review of currently published
studies show the advantages of the ileostomy [48]. A large
Swedish randomised trial showed a reduction in leak rate in
patients with stoma and a better long-term outcome [49].
Therefore, a deviating stoma is recommended when per-
forming TME in rectal cancer surgery. These data should
be extrapolated to laparoscopic surgery. In laparoscopic
surgery, results of comparative trials in similar clinical
situation show a reduction in the intensity of peritonitis
when the anastomosis is diverted or not [112]. Especially
after neoadjuvant chemoradiotherapy a stoma (ileostomy
or colostomy) is advisable in laparoscopic rectal cancer
surgery.
Very low rectal cancer, with infiltration into the external
sphincter or pelvic floor, should be treated by APR. (85.7%
[Consensus]; GoR B: 92.9% [Consensus])
Classical APR implies a laparoscopic mobilization of
the rectum followed by perineal resection in lithotomy
position. Prone position for the perineal cylindrical exci-
sion is proposed. (85.7% [Consensus]; GoR C: 92.9%
[Consensus])
Mobilization of the rectum by laparoscopy has to be
performed as deep as possible in the pelvic floor, to a level
where there is no risk of compromising the surgical plane
[113–118].
There are two different approaches for the perineal
phase: the classical perineal resection between the legs in
lithotomy position, and the extralevator perineal resection
performed in prone position [119]. During the first
approach the perineal excision is performed, the specimen
resected and retrieved (waist model), presacral space
drained and wound approximated in layers, whereas in the
extralevator excision the resected specimen has cylindrical
shape. It is currently suggested that R0 resections and
circumferential resection margins (CRM) involvement are
improved in the extralevator resection [120].
The defect after perineal excision can be approximated,
whereas after extralevator dissection it can be closed by
means of a muscular flap. (92.9% [Consensus]; GoR C:
92.9% [Consensus])
In lithotomy position, closure methods to occlude the
pelvis can include the use of the greater omentum, closure
of the peritoneum or leaving the peritoneum and the pelvis
open. To close a huge perineal defect after extralevator
excision, reconstruction of pelvic floor will be accom-
plished by means of unilateral or bilateral m. gluteus
maximus flap reconstruction, a vertical m. rectus abdo-
minis flap or a transverse m. rectus abdominis flap [121].
Other possibilities of reconstruction such as use of pros-
thetic materials are considered as exceptional and routinely
not recommended.
Quality and outcome analysis
Laparoscopic approach for curative rectal cancer must
offer the same quality of the surgical specimen as in open
surgery. Pathology analysis must include assessment of the
following: completeness of the mesorectum, CRM, distal
margin and number of lymph nodes. (100% [Strong con-
sensus]; GoR A: 92.9% [Strong consensus])
Laparoscopic approach to TME is not inferior to the
open in terms of disease-free survival (DFS), overall sur-
vival (OS) or local recurrence. (92.9% [Consensus];
GoR B: 85.7% [Consensus])
The final goal in rectal cancer surgery using total mes-
orectal excision is to reduce the incidence of local recur-
rence to a minimum rate. Current results of multiple single-
centre and multicentre experiences in open surgery estab-
lished a recurrence rate below 5–7% [32, 35]. The initial
results obtained from single-centre experiences show the
ability of laparoscopic approach to obtain mesorectal
specimens that achieve the standards of pathology quality
and a local recurrence rate below 6%. In a recent study
analysing the Spanish registry of rectal cancer there were
no differences in the quality of the mesorectum between
the open and the laparoscopic approach. Six hundred four
patients operated between 2006 and 2008 (209 laparo-
scopic and 395 open) were included. This study did not
show differences in the number of lymph nodes retrieved,
status of the CRM or in the quality of the mesorectum
Surg Endosc (2011) 25:2423–2440 2431
123
(complete 77%, nearly complete 15%, incomplete 8%).
However, the shortcomings of this study are diverse: it is a
voluntary registry, not randomised and obviously selected,
with more difficult cases included in the open group [122].
In a recent single-center prospective randomised trial Lujan
et al. could not find any differences in the quality of the
mesorectum or in the rates of local recurrence [88].
However, these trials still have the drawbacks of selection
bias, and this topic should be analysed carefully in multi-
center prospective randomised trials that would permit to
demonstrate the safety of the laparoscopic approach to low
rectal cancer.
The laparoscopic approach permits to obtain similar
long-term outcome, in terms of disease-free or overall
survival, as in open surgery. Table 1 presents the long-term
outcome from the most important series observed up to
now, showing DFS, OS and local recurrence similar to
open surgery. Recently, Laurent et al. [123] presented
outcome data from a comparative study including 500
patients (Tables 1, 2). The main results of this study were
the absence of differences in relation to local recurrence
(LR) and DFS. Additionally this study reported that the
type of approach did not influence the cancer outcome, as
well as that the conversion (36/238, 15%) did not have a
negative impact on postoperative mortality, local recur-
rence or survival [123].
Laparoscopic resection is slightly superior to open in
terms of short-term outcome (reduced hospital stay,
improved bowel function and reduced pain). (92.9%
[Consensus]; GoR B: 85.7% [Consensus])
Initial results show that laparoscopic approach to rectal
cancer is followed by the accepted advantages of endo-
scopic surgery in terms of less pain, faster recovery and
better immediate outcome compared with open cases.
Breukink et al. [124] published in 2006 a metanalysis of 48
studies including 4,224 cases. The quality of the trials
included in this metanalysis were diverse [3 grade 1b
(individual randomised trial), 12 grade 2b (individual
cohort study), 5 grade 3b (individual case–control study)
and 28 grade 4 (case series)]. This meta-analysis did not
show differences in DFS, LR, mortality, morbidity, leak-
age, CRM or number of lymph nodes. Laparoscopic TME
was associated with less blood loss, faster return to normal
diet, less pain, less narcotic use and less immune response.
On the other hand the laparoscopic approach was followed
by longer operative time and higher costs. The conclusion
of this analysis was that the laparoscopic approach
appeared to have clinically short-term advantages in
patients with primary resectable rectal cancer. The long-
term impact on oncological endpoints awaits the findings
from large ongoing randomised trials. Table 2 reports the
results of the more important series published.
Laparoscopic resection is superior to open in terms of
reduced surgical-site infections. (92.9% [Consensus];
GoR B: 85.7% [Consensus])
Two recent studies [125, 126] have shown the definitive
advantage of laparoscopic approach in terms of incidence
and severity of postoperative surgical-site infection
(SSI). Varela et al. [125] have recently observed in a large
cohort of patients [laparoscopic (n = 94,665) or open
(n = 36,965) appendectomy, cholecystectomy, antireflux
surgery or gastric bypass between 2004 and 2008]. Overall,
the incidence of SSI was significantly lower in laparo-
scopic (483 of 94,665, 0.5%) than in open (669 of 36,965,
1.8%) surgery (p \ 0.01). The study permits to conclude
that patients treated with laparoscopic procedures are less
likely to experience SSI. After stratification by severity of
illness, admission status and wound classification, laparo-
scopic techniques showed a protective effect against SSI.
In another recent study [126] Dobson et al. analysed the
need for emergency department evaluation, hospital read-
mission and re-operation after colorectal surgery in 603
laparoscopic versus 2,246 open patients prospectively
recorded. Although SSI was identified in 5.8% of the lap-
aroscopic group and 4.8% in the open group, emergency
department evaluation for infection was needed in only
24% of the laparoscopic patients versus 42% in open sur-
gery. Also hospital readmission (1% laparscopic versus
Table 1 Laparoscopic rectal cancer surgery, long-term oncological outcome: follow-up, 5-year overall survival (OS), 5-year disease-free
survival (DFS), local recurrence (LR) and type of study with level of evidence (LoE)
N Follow-up 5-Year OS 5-Year DFS LR Type of study LoE
(months) (%) (%) (%)
Anthuber [152] 2003 101 17 – – 2 Individual cohort study 2b
Morino [78] 2003 70 45.7 74 63 4.2 Case series 4
Leroy [80] 2004 98 36 65 75 6 Case series 4
Tsang [153] 2006 105 26.9 76.9 64.4 8.9 Case series 4
Agha [154] 2008 225 46.4 69.2 85.7 5.8 Case series 4
Laurent [123] 2009 238/233 52 83/72 82/79 3.9/5.5 Individual case–control study 3b
Laparoscopy/Open
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52% open) and re-operation (0% laparoscopic versus 12%
open) were both significantly less common and permitted to
conclude that laparoscopic colorectal surgery patients
experienced less severe morbidity when they developed SSI
and required fewer healthcare resources to manage their
wounds compared with open colorectal surgery patients.
Postoperative morbidity rate after laparoscopic
approach to the rectum seems to be similar/slightly lower
than after open surgery. (85.7% [Consensus]; GoR B:
85.7% [Consensus])
Postoperative morbidity after laparoscopic approach to
the rectum seems to be similar/slightly lower than after
open surgery. This issue cannot be definitively assessed
until the results of large multicenter RCT are available. A
cautionary note should be commented in relation to the
anastomotic leak rate, in relation to the difficulty observed
for low rectal transection in the obese or in those with a
narrow pelvis space. As commented before, surgical-site
infections are expected to be lower when the laparoscopic
approach is used.
The laparoscopic approach permits to obtain a similar
sphincter-preservation rate, without impact on the number
of definitive stoma. (92.9% [Consensus]; GoR B: 85.7%
[Consensus])
The lack of adequately powered RCT does not permit to
definitively conclude whether the laparoscopic approach to
rectal cancer is associated with a similar rate of sphincter
preservation or definitive stoma. Preliminary results from
single series and RCT do not show any differences
regarding the rate of definitive stoma, and due to the better
visualization of the deep pelvis, the number of sphincter
preservations may be increased.
There are no definitive data in relation of quality of life
(QoL) after laparoscopic surgery of the rectum; however,
data extrapolated from trials including rectosigmoid
resection seem to confer a slight short-term improvement of
QoL after laparoscopic surgery. (92.9% [Consensus])
It is well established that, after colorectal laparoscopic
surgery, immediate QoL is superior to that after open
surgery [127–129]. This advantage may be extrapolated to
low rectal cancer cases, mainly because some of these trials
included rectosigmoid resections, but there are no data
available in relation to rectal surgery. A logical inference is
to assume that this improvement could be extrapolated to
rectal surgery, but in this situation, the most detrimental to
QoL are the existence of a stoma or poor anorectal func-
tion, aspects that are not related intrinsically to the lapa-
roscopic approach. For all these reasons, further specific
information regarding this clinical point is necessary.
Anorectal function has a similar outcome after laparo-
scopic and open surgery. Laparoscopic pelvic dissection
may impair genitourinary function after rectal resection,
like open surgery. Sexual function is a point of concern.
(92.9% [Consensus])
Pelvic exploration is improved by the laparoscopic
approach due to better visualization of the structures, but
identification of the tiny nervous structures especially in
the lower pelvis continues to be hazardous. On the other
hand the need for retraction as well as energy sources used
in laparoscopic surgery may impair/cause injury to deep
pelvic structures. Laparoscopic pelvic dissection may
impair bladder function after rectal resection, like in open
surgery. Sexual function is a point of concern, and several
studies have shown detrimental effects on postoperative
sexual function, but without a clear consensus (Table 3).
There is a lack of information in relation to anorectal
function after laparoscopic dissection of the rectum. Ano-
rectal function is severely impaired by previous radio-
therapy, but the laparoscopic approach does not seem to
impair/improve this function. Further studies focussed on
Table 2 Laparoscopic rectal cancer surgery, short-term outcomes: operating time (OP-time), conversion rate, hospital stay, mortality, morbidity
and type of study with level of evidence (LoE)
N OP-time
(min)
Conversion
(%)
Hospital stay
(days)
Mortality
(%)
Morbidity
(%)
Type of study LoE
Quah [151] 2002
Laparoscopy/Open
86/84 – 12 – – – RCT 1b
Anthuber [152] 2003
Laparoscopy/Open
101/334 218/219 10.9 14.4/19.9 0/1.5 30.7/65 Individual cohort study 2b
Morino [78] 2003 100 250 12 16.6 2 36 Case series 4
Rullier [111] 2003 32 420 9.3 9 3.1 31.2 Individual cohort study 2b
Leroy [80] 2004 102 202 3 11.9 2 27 Case series 4
Tsang [153] 2006 105 170 1.9 10.1 0 24.7 Case series 4
Agha [154] 2008 225 217 10.2 13.8 1.3 35.6 Case series 4
Laurent [123] 2009
Laparoscopy/Open
238/233 – 15.1 9/16 0.8/2.6 32/37.7 Individual case–control study 3b
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these important items are needed to identify the possible
detrimental factors of the laparoscopic approach.
Direct costs after laparoscopic surgery of the rectum
are similar or slightly higher than after open surgery.
(85.7% [Consensus])
The scarce data from different studies show uniformly
that costs of the laparoscopic approach are higher than after
open surgery [130–134]. Arteaga [135] showed an increase
in OR costs that balanced with a shorter hospital stay to
make total hospital costs similar. All health economy
analyses must be used with care, as differences in national
health systems and reimbursement systems differ widely.
In many systems the direct costs in OR can rarely be
compensated in another budget.
Special and new surgical techniques
TEM and transanal local excision
Patients with T1 cancer and favourable histological fea-
tures may undergo local excision alone. (85.7% [Consen-
sus]; GoR B: 78.6% [Consensus])
When local excision is indicated, transanal endoscopic
microsurgery (TEM) is the preferred technique. (92.9%
[Consensus]; GoR B: 79.6% [Consensus])
Patient selection is the most important factor in suc-
cessful local excision; however, specific criteria for
selecting patients have not been universally accepted.
Local treatment of rectal cancer aims to decrease the
morbidity and the functional sequelae associated with
radical surgery without compromising local tumour control
and long-term survival.
Patients with localised superficial tumour (uT1, uN0)
may undergo local excision alone. Other additional criteria
are tumour size less than 4 cm and well- or moderately
well-differentiated histology. The probability of lymph
node metastases for a T1 G1 (well-differentiated) tumour is
around 0% compared with more than 10% for a T1 G3
(poorly differentiated) tumour [136].
Full-thickness excision of the tumour with lateral mar-
gin of 1 cm and clear margin to the perirectal tissue
without tumour fragmentation is essential. This approach
allows accurate assessment of histopathological parameters
such as margin, differentiation, vascular involvement and
depth of penetration [137, 138].
When a local excision is indicated, the minimally
invasive endoscopic technique transanal endoscopic
microsurgery (TEM) is the preferred technique. Gerhard
Bueß originally developed TEM in the 1980s [139, 140].
Conventional transanal excision is mostly limited to low
rectal lesions, whereas TEM is preferably used for lesions
in the middle and upper third of the rectum that are inac-
cessible by conventional transanal excision. TEM has
been proved to be safe and effective in several case series
Table 3 Laparoscopic rectal cancer surgery, post-operative urinary and sexual function: year of publication, type of study and level of evidence
(LoE)
Year of
publication
Urinary function Sexual function Type of
study
LoE
Quah [151]
Laparoscopy/
Open
2002 No significant deterioration
No differences lap versus open
Impaired in male, but not in female
Subgroup of sexually active male significantly impaired in
lap versus open
RCT 1b
Jayne [155]
Laparoscopy/
Open
2005 Bladder dysfunction (global) in
35%
No differences lap versus open
Impaired
In male, overall sexual function ? erectile function tended
to be worse in lap versus open
RCT 1b
Liang [156] 2007 Voiding function—71.6%
good, 23% fair, 5.4% poor
Female—53.6% good, 14.3% fair, 32.1% poor
Male-ejaculation/potency—56.3/62.5% good, 18.7/14.3%
fair, 25/21.9% poor
Case
series
4
Breukink
[157]
2008 Quality of life due to urinary
symptoms significantly
decreased
With regard to specific
symptoms, only frequency
significantly worsened
No significant differences except of intercourse satisfaction Case
series
4
Asoglu [158]
Laparoscopy/
Open
2009 No differences Significantly higher rate of sexual dysfunction in open
versus lap (in both female and male)
Individual
cohort
study
2b
Morino [159] 2009 No significant differences,
except for a postoperative
weak stream
Sexual desire was maintained by 55.6%, ability to engage in
intercourse by 57.8%, and ability to achieve orgasm and
ejaculation by 37.8% of the male patients
Case
series
4
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[141, 142]. Although the evidence regarding TEM is lim-
ited, it does appear to result in fewer recurrences compared
with conventional transanal excision [143, 144].
NOTES and single port
No recommendations were established at the consensus
conference considering natural orifice transluminal endo-
scopic surgery (NOTES) and single-incision laparoscopic
surgery (SILS). No available data with regard to SILS and
NOTES on rectal cancer exist. (100% [Strong consensus])
According to the EAES recommendations on method-
ology of innovation management in endoscopic surgery,
feasibility and preclinical safety must be established before
innovations such as NOTES and SILS become subject of
clinical research [145].
Within the last years, significant research efforts have
focussed on developing safe and reproducible transluminal
endoscopic approaches to perform various intra-abdominal
procedures [146]. Recently a first clinical case of NOTES
transanal resection for rectal cancer using TEM and lapa-
roscopic assistance has been reported [147]. Improvements
in NOTES instrumentation and careful patient selection
may allow further clinical application within controlled
clinical trials to evaluate safety and outcome of this
approach.
Conclusions
Laparoscopic surgery for middle and low rectal cancer can
be recommended under optimal conditions (expert sur-
geons, expert centres, selected patients, excluding T4).
(85.7% [Consensus]; GoR B: 85.7% [Consensus])
The vast majority of the panel would recommend the
laparoscopic approach for rectal cancer surgery. Still,
upcoming results from large randomised trials are awaited to
strengthen the evidence for improved short-term results and
equal long-term results in comparison with open surgery.
After the recommendations above were presented, data
from two randomised controlled trials have been published
[148, 149]. These results strengthen our recommendations
by confirming the safety of the laparoscopic approach and
providing evidence for no difference in long-term outcome.
In July 2010, Kang et al. published the short-term out-
comes of the comparison of open versus laparoscopic
surgery for mid and low rectal cancer after neoadjuvant
chemoradiotherapy (COREAN) trial, a randomised con-
trolled, multicentre study. Analysis of the criteria associ-
ated with long-term oncological outcome such as quality of
TME, CRM positivity and number of lymph nodes showed
very good results similar to open surgery (incomplete TME
in 4.7% of laparoscopic cases versus 6.5% in open surgery,
positive CRM of 2.9% in the laparoscopic group versus
4.1% in the open group, and median 17 lymph nodes versus
18). Furthermore, the authors report a very low conversion
rate of 1.2% and confirmed the known recovery benefits of
the laparoscopic approach such as fewer wound compli-
cations, less pain and better recovery of intestinal function.
These results show that excellent outcomes can be
achieved by the laparoscopic approach in expert hands
[148].
The 5-year analyses of the Medical Research Council
CLASICC trial of laparoscopically assisted versus open
surgery for colorectal cancer were published online in July
2010. There was no difference in OS or DFS for patients
with rectal cancer with respect to the randomised proce-
dure. For rectal cancer, the 5-year OS rate was 52.9% for
open versus 60.3% for laparoscopic surgery; the 5-year
DFS rate was 52.1% for open versus 53.2% for laparo-
scopic surgery. In patients undergoing anterior resection,
the previously reported differences in CRM positivity rates
did not translate into a difference in the 5-year local
recurrence rate: 7.6% for open versus 9.4% for laparo-
scopic surgery (p = 0.740) [149].
Recently, the COLOR II trial comparing laparoscopic
and open rectal cancer surgery within a multicentre and
multinational setting completed inclusion of more than
1,100 patients. When the panel members demonstrated the
first consensus on these recommendations at the 18th
International Congress of the EAES in Geneva, Jaap
Bonjer presented the first data of the COLOR II trial after
recruitment was closed some days before. As of May 2010,
1,103 patients with rectal cancer have been randomised in
30 sites in 8 countries. Valid short-term results from this
trial should be released soon, whereas long-term results
may be available in some years only [97, 150].
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